Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3H-10000 in Unresectable or Metastatic Advanced Solid Tumors
CTR20254555Phase 2Active
- Sponsor
- Sikang Ruiqi
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 3H-10000 in Nonhematologic neoplasms, sponsored by Sikang Ruiqi. Started Nov 2025; status: active.
02
Drugs
3H-10000
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254555.